Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
Publication/Presentation Date
2-1-2008
Abstract
OBJECTIVE: Pharmacological inhibition with the dipeptidyl peptidase 4 (DPP-4) inhibitor vildagliptin prolongs the action of endogenously secreted incretin hormones leading to improved glycemic control in patients with type 2 diabetes mellitus (T2DM). We undertook a double-blinded, randomized-order, crossover study to examine the vildagliptin mechanisms of action on islet function and glucose utilization.
RESEARCH DESIGN AND METHODS: Participants with T2DM (n = 16) who had a baseline hemoglobin A(1c) of 7.1 +/- 0.2% completed a crossover study with 6 wk of treatment with vildagliptin and 6 wk with placebo. At the completion of each arm, participants had a study of postprandial metabolism and a two-step glucose clamp performed at 20 and 80 mU/min x m(2) insulin infusions.
RESULTS: Vildagliptin increased postprandial glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide by 3- and 2-fold, respectively, reduced fasting plasma glucose and postprandial plasma glucose by 1.3 +/- 0.3 mmol/liter and 1.6 +/- 0.3 mmol/liter (both P
CONCLUSIONS: Vildagliptin improves islet function in T2DM and improves glucose metabolism in peripheral tissues.
Volume
93
Issue
2
First Page
459
Last Page
464
ISSN
0021-972X
Published In/Presented At
Azuma, K., Rádiková, Z., Mancino, J., Toledo, F. G., Thomas, E., Kangani, C., Dalla Man, C., Cobelli, C., Holst, J. J., Deacon, C. F., He, Y., Ligueros-Saylan, M., Serra, D., Foley, J. E., & Kelley, D. E. (2008). Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. The Journal of clinical endocrinology and metabolism, 93(2), 459–464. https://doi.org/10.1210/jc.2007-1369
Disciplines
Medicine and Health Sciences
PubMedID
18042650
Department(s)
Fellows and Residents
Document Type
Article